Drug application
BREVICON 21-DAY (ETHINYL ESTRADIOL, NORETHINDRONE)
Drugs@FDA NDA 017566 · ALLERGAN
Key facts
| Drug name | BREVICON 21-DAY |
|---|---|
| Active ingredients | ETHINYL ESTRADIOL, NORETHINDRONE |
| Application type | NDA |
| Application number | 017566 |
| Company | ALLERGAN |
| Dosage forms | TABLET, ORAL-21 |
| Strength | 0.035MG;0.5MG |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 5 - New Formulation or New Manufacturer |
| Latest submission status date | Dec 26, 1974 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: